HK1119681A1 - 7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7h-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-c]-pyrimidin-5 amine - Google Patents
7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7h-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-c]-pyrimidin-5 amineInfo
- Publication number
- HK1119681A1 HK1119681A1 HK08111733.1A HK08111733A HK1119681A1 HK 1119681 A1 HK1119681 A1 HK 1119681A1 HK 08111733 A HK08111733 A HK 08111733A HK 1119681 A1 HK1119681 A1 HK 1119681A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- benzisoxazol
- triazolo
- pyrazolo
- pyrimidin
- propynyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72002705P | 2005-09-23 | 2005-09-23 | |
PCT/US2006/037003 WO2007038284A1 (en) | 2005-09-23 | 2006-09-21 | 7-[2-[4-(6-FLUORO-3-METHYL-1,2-BENZISOXAZOL-5-YL)-1-PIPERAZINYL]ETHYL]-2-(1-PROPYNYL)-7H-PYRAZOLO-[4,3-e]-[1,2,4]-TRIAZOLO-[1,5-c]-PYRIMIDIN-5 AMINE |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1119681A1 true HK1119681A1 (en) | 2009-03-13 |
Family
ID=37487759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK08111733.1A HK1119681A1 (en) | 2005-09-23 | 2008-10-24 | 7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7h-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-c]-pyrimidin-5 amine |
Country Status (31)
Country | Link |
---|---|
US (2) | US7572802B2 (xx) |
EP (1) | EP1937687B1 (xx) |
JP (1) | JP4808779B2 (xx) |
KR (1) | KR101396614B1 (xx) |
CN (2) | CN102716131B (xx) |
AR (1) | AR056080A1 (xx) |
AT (1) | ATE503759T1 (xx) |
AU (1) | AU2006294633B8 (xx) |
BR (1) | BRPI0616264B8 (xx) |
CA (1) | CA2623047C (xx) |
CY (1) | CY1111921T1 (xx) |
DE (1) | DE602006021042D1 (xx) |
DK (1) | DK1937687T3 (xx) |
EC (1) | ECSP088297A (xx) |
ES (1) | ES2361856T3 (xx) |
HK (1) | HK1119681A1 (xx) |
HR (1) | HRP20110466T1 (xx) |
IL (1) | IL190275A (xx) |
MY (1) | MY146429A (xx) |
NO (1) | NO341760B1 (xx) |
NZ (1) | NZ566737A (xx) |
PE (1) | PE20070521A1 (xx) |
PL (1) | PL1937687T3 (xx) |
PT (1) | PT1937687E (xx) |
RS (1) | RS51702B (xx) |
RU (1) | RU2417997C2 (xx) |
SG (1) | SG165419A1 (xx) |
SI (1) | SI1937687T1 (xx) |
TW (1) | TWI335329B (xx) |
WO (1) | WO2007038284A1 (xx) |
ZA (1) | ZA200802550B (xx) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ527142A (en) | 2003-07-23 | 2006-03-31 | Douglas Pharmaceuticals Ltd | A stable suspension formulation |
US7723343B2 (en) * | 2007-03-30 | 2010-05-25 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2A receptor antagonists |
WO2010103547A2 (en) | 2009-03-13 | 2010-09-16 | Advinus Therapeutics Private Limited | Substituted fused pyrimidine compounds |
EP2462144B1 (en) * | 2009-08-07 | 2017-09-20 | Merck Sharp & Dohme Corp. | PROCESS FOR PREPARING A 2-ALKYNYL SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE |
WO2011101861A1 (en) | 2010-01-29 | 2011-08-25 | Msn Laboratories Limited | Process for preparation of dpp-iv inhibitors |
AU2011306358B2 (en) * | 2010-09-24 | 2014-08-14 | Impetis Biosciences Ltd. | Fused tricyclic compounds as adenosine receptor antagonist |
WO2012135083A1 (en) * | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | METABOLITES OF 7-(2-(4-(6-FLUORO-3-METHYLBENZO[d]ISOXAZOL-5-YL)PIPERAZIN-1-YL)ETHYL)-2-(PROP-1-YNYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
WO2014101113A1 (en) * | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
WO2014101120A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
JPWO2014128882A1 (ja) * | 2013-02-21 | 2017-02-02 | 医療法人 和楽会 | 不安うつ病の治療薬 |
WO2015027431A1 (en) * | 2013-08-29 | 2015-03-05 | Merck Sharp & Dohme Corp. | 2,2-difluorodioxolo a2a receptor antagonists |
WO2016071293A2 (en) | 2014-11-03 | 2016-05-12 | Iomet Pharma Ltd | Pharmaceutical compound |
WO2016089796A1 (en) * | 2014-12-04 | 2016-06-09 | Merck Sharp & Dohme Corp. | Formulation inhibiting effects of low acid environment |
CN106543095B (zh) * | 2016-09-23 | 2019-03-05 | 江苏大学 | 一种基于2-羟基苯乙酮肟及其衍生物一锅制备苯并异噁唑的方法 |
EP3723754A4 (en) | 2017-12-13 | 2021-05-19 | Merck Sharp & Dohme Corp. | IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES |
CN110742893B (zh) * | 2018-07-23 | 2024-04-05 | 百济神州(北京)生物科技有限公司 | A2a受体拮抗剂治疗癌症的方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE462170B (sv) | 1987-10-27 | 1990-05-14 | Aahlstrom Corp | Avlaegsnande av loesta och kolloidala makromolekylaera organiska aemnen ur effluenter |
IT1264901B1 (it) | 1993-06-29 | 1996-10-17 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina |
WO1995003806A1 (fr) | 1993-07-27 | 1995-02-09 | Kyowa Hakko Kogyo Co., Ltd. | Remede contre la maladie de parkinson |
IT1275420B (it) | 1995-06-02 | 1997-08-05 | Schering Plough S P A | Metodo per misurare l'affinita' di legame al recettore a2a dell'adenosina di componenti di interesse farmacologico mediante l'uso del ligando triziato (3h)-sch 58261 |
IT1277392B1 (it) | 1995-07-28 | 1997-11-10 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina |
IT1291372B1 (it) | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
ATE293627T1 (de) | 2000-05-26 | 2005-05-15 | Schering Corp | Adenosin a2a rezeptor antagonisten |
GB0100624D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
IL160878A0 (en) * | 2001-10-15 | 2004-08-31 | Schering Corp | Imidazo (4,3-e)-1,2,4-triazolo (1,5-c) pyrimidines as adenosine a2a receptor antagonists |
CN100415217C (zh) | 2002-12-19 | 2008-09-03 | 先灵公司 | 腺苷A2a受体拮抗剂的应用 |
MY139344A (en) * | 2003-04-23 | 2009-09-30 | Schering Corp | 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists |
US7709492B2 (en) | 2004-04-21 | 2010-05-04 | Schering Corporation | Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists |
-
2006
- 2006-09-20 PE PE2006001140A patent/PE20070521A1/es active IP Right Grant
- 2006-09-20 AR ARP060104110A patent/AR056080A1/es active IP Right Grant
- 2006-09-21 SG SG201006970-6A patent/SG165419A1/en unknown
- 2006-09-21 RS RS20110262A patent/RS51702B/en unknown
- 2006-09-21 AT AT06804036T patent/ATE503759T1/de active
- 2006-09-21 CN CN201110394181.7A patent/CN102716131B/zh not_active Expired - Fee Related
- 2006-09-21 NZ NZ566737A patent/NZ566737A/en not_active IP Right Cessation
- 2006-09-21 PL PL06804036T patent/PL1937687T3/pl unknown
- 2006-09-21 CA CA2623047A patent/CA2623047C/en not_active Expired - Fee Related
- 2006-09-21 US US11/525,065 patent/US7572802B2/en active Active
- 2006-09-21 RU RU2008115239/04A patent/RU2417997C2/ru active
- 2006-09-21 WO PCT/US2006/037003 patent/WO2007038284A1/en active Application Filing
- 2006-09-21 TW TW095134895A patent/TWI335329B/zh not_active IP Right Cessation
- 2006-09-21 SI SI200631017T patent/SI1937687T1/sl unknown
- 2006-09-21 AU AU2006294633A patent/AU2006294633B8/en not_active Ceased
- 2006-09-21 ES ES06804036T patent/ES2361856T3/es active Active
- 2006-09-21 KR KR1020087007052A patent/KR101396614B1/ko active IP Right Grant
- 2006-09-21 CN CN2006800352004A patent/CN101273045B/zh not_active Expired - Fee Related
- 2006-09-21 BR BRPI0616264A patent/BRPI0616264B8/pt not_active IP Right Cessation
- 2006-09-21 EP EP06804036A patent/EP1937687B1/en active Active
- 2006-09-21 PT PT06804036T patent/PT1937687E/pt unknown
- 2006-09-21 DE DE602006021042T patent/DE602006021042D1/de active Active
- 2006-09-21 JP JP2008532422A patent/JP4808779B2/ja not_active Expired - Fee Related
- 2006-09-21 DK DK06804036.9T patent/DK1937687T3/da active
- 2006-09-21 MY MYPI20080750A patent/MY146429A/en unknown
-
2008
- 2008-03-18 IL IL190275A patent/IL190275A/en active IP Right Grant
- 2008-03-19 EC EC2008008297A patent/ECSP088297A/es unknown
- 2008-03-19 ZA ZA200802550A patent/ZA200802550B/xx unknown
- 2008-04-22 NO NO20081924A patent/NO341760B1/no not_active IP Right Cessation
- 2008-10-24 HK HK08111733.1A patent/HK1119681A1/xx not_active IP Right Cessation
-
2009
- 2009-07-06 US US12/498,013 patent/US8389532B2/en active Active
-
2011
- 2011-06-20 HR HR20110466T patent/HRP20110466T1/hr unknown
- 2011-06-28 CY CY20111100618T patent/CY1111921T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL190275A0 (en) | 7-[2-[4-(6-FLUORO-3-METHYL-1,2-BENZISOXAZOL-5-YL)-1-PIPERAZINYL]ETHYL]-2-(1-PROPYNYL)-7H-PYRAZOLO-[4,3-e]-[1,2,4]-TRIAZOLO-[1,5-c]-PYRIMIDIN-5 AMINE | |
AP2006003767A0 (en) | Morpholine compounds | |
HK1104175A1 (en) | Pyrrolopyridine derivatives | |
ATE415400T1 (de) | Pyrazolopyridinderivate | |
EP1732566A4 (en) | 6-azaindole COMPOUND | |
IL180481A0 (en) | Aryl-pyridine derivatives | |
IL177968A0 (en) | Tetrahydropyridoindole derivatives | |
HK1105971A1 (en) | Pyrrazolo-pyrimidine derivatives | |
EP1801108A4 (en) | morpholine | |
ZA200608589B (en) | Dosage form having polymorphic stability | |
IL182585A0 (en) | Imidazo-benzodiazepine derivatives | |
IL182697A0 (en) | Halogen substituted benzodiazepine derivatives | |
HK1100002A1 (en) | 4-phenyl-pyrimidine-2-carbonitrile derivatives | |
HK1100775A1 (en) | 4-Amino-5-cyanopyrimidine derivatives | |
GB0414272D0 (en) | OsK1 derivatives | |
GB2433993B (en) | Single molecule TR-FRET probe | |
PL1798356T3 (pl) | Układ cokołowego końcowego profilu tynkarskiego | |
ZA200609864B (en) | Pyrrolopyridine derivatives | |
GB0423007D0 (en) | Foldable chair for bathroom | |
GB0326148D0 (en) | Morpholine derivatives | |
ZA200702343B (en) | Aminoalcohol derivatives | |
GB0422398D0 (en) | Pyridopyrimidine derivatives | |
GB0422395D0 (en) | Pyrimidopyrimidine derivatives | |
GB0406657D0 (en) | The use of non-opiates for the potentiation of opiates | |
HU0400338D0 (en) | New substituted benzodiazepine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20220921 |